Skip header and navigation

11 records – page 1 of 2.

Document Type
Evidence Search Report
Review Code
EOC211201-02 ESR
Question Submitted
December 23, 2021
Date Completed
January 5, 2022
Status
3. Completed
Research Team
EOC
/contact_mngm t/management_cases_contacts_omicron.pdf UK Health Security Agency  SARS-CoV-2 variants
Document Type
Evidence Search Report
Review Code
EOC211201-02 ESR
Question Submitted
December 23, 2021
Date Completed
January 5, 2022
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Epidemiology
Subject
Antigens
Infection Prevention and Control
Testing
Variants
Population
All
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Miller, Lukas. Howell-Spooner, Brianna. Omicron Variant: In real world settings, what is the validity of RATs in identifying COVID-19 (sensitivity, specificity), and how well do they predict disease (positive and negative predictive values)? 2022 Jan 05. Document no.: EOC211201-02 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PH030801 RR
Question Submitted
March 8, 2021
Date Completed
March 30, 2021
Status
6. Cancelled
Research Team
Public Health
Review Title: What are the effects of the new COVID variants on transmission and school reopenings
Document Type
Rapid Review
Review Code
PH030801 RR
Question Submitted
March 8, 2021
Date Completed
March 30, 2021
Status
6. Cancelled
Research Team
Public Health
Key Findings
Pediatric cases of COVID-19 constitute between 1% to 10% of all confirmed cases of COVID-19; variation exists by jurisdiction.
Few case reports exist of confirmed child-to-other transmission. Contact tracing studies suggest that children are unlikely to be transmitters of the disease. Households are the most likely environments for transmission.
A recent large South Korean contact tracing study however (in pre-print) found that household COVID-19 transmission rates for children age 10-19 were significantly higher than in adults; transmission rates for children age 0-9 were relatively low.
AUGUST 7th, 2020 UPDATE: No new studies examining secondary attack rates of pediatric index cases were found. Studies continue to suggest low transmission from pediatric cases, and high proportion of pediatric cases being asymptomatic to mildly symptomatic.
MARCH 9th, 2021 UPDATE: Variants of Concerns are an emerging threat, but literature on pediatric prevalence and transmissibility is sparse. The British variant seems more transmissible (secondary attack rate higher) but follows the same age-related distribution of cases seen earlier in the pandemic.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Variants
Pediatrics
Transmission
Schools
Population
All Pediatrics
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Sulaiman, F; Coomaran, V; Muhajarine, N; Dalidowicz, M; Miller, L. What are the effects of the new COVID variants on transmission and school reopenings in pediatric populations? 2021 Mar 30; Document no.: PH030801 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14p. (CEST rapid review report)
Similar Reviews
EOC072102-01 ESR
EOC070201v2-01 ESR
EOC081201-01 ESR
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PH030801v2 ESR
Question Submitted
March 8, 2021
Date Completed
August 18, 2021
Status
6. Cancelled
Research Team
Public Health
EVIDENCE SEARCH REPORT Review Question: What are the effects of the new COVID variants on transmission
Document Type
Evidence Search Report
Review Code
PH030801v2 ESR
Question Submitted
March 8, 2021
Date Completed
August 18, 2021
Status
6. Cancelled
Research Team
Public Health
Notes
Work was not completed before the project was no longer supported
Category
Epidemiology
Infection Prevention and Control
Subject
Variants
Pediatrics
Transmission
Schools
Population
All Pediatrics
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Howell-Spooner, B., Mueller, M. What are the effects of the new COVID variants on transmission and school reopenings in pediatric populations? 2021 Aug 18, Document no.: PH030801v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 49 p. (CEST evidence search report).
Similar Reviews
EOC072102-01 ESR
EOC070201v2-01 ESR
EOC081201-01 ESR
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC211220 RR Table
Question Submitted
December 20, 2021
Date Completed
December 22, 2021
Status
3. Completed
Research Team
EOC
variants of concern and variants under investigation in England. Technical briefing 31. 10 December 2021
Document Type
Table
Review Code
EOC211220 RR Table
Question Submitted
December 20, 2021
Date Completed
December 22, 2021
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Healthcare Services
Subject
Variants
Health Planning
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Reeder, B; Groot, G; Miller, L. What is the epidemiology of the Omicron variant and its impact on health care? 2021 Dec 22, Document no.: EOC211220 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table).
Related Documents
Documents

EOC211220 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC211220 RR
Question Submitted
December 20, 2021
Date Completed
December 22, 2021
Status
3. Completed
Research Team
EOC
lower than protection against other variants  Vaccination protection against severe disease appears
Document Type
Rapid Review
Review Code
EOC211220 RR
Question Submitted
December 20, 2021
Date Completed
December 22, 2021
Status
3. Completed
Research Team
EOC
Key Findings
December 22, 2021
Omicron first detected in Botswana and South Africa at the end of November 2021, classified as a variant of concern by the WHO and CDC by December 1st, 2021 after rapid spread to multiple areas of the world, and evidence of community transmission
Preliminary data indicates increased transmissibility of Omicron compared to the currently dominant Delta
In-vitro data indicates a significant reduction in neutralization titers of vaccinee sera – however, sera from individuals recently boosted with an mRNA vaccine had a minimal reduction in neutralization capacity compared to Delta
Increasing rates of breakthrough infections in South Africa and the UK confirming suspicions of decreased vaccine effectiveness of primary vaccine series, early data shows that mRNA boosters increase levels of protection, though still lower than protection against other variants
Vaccination protection against severe disease appears to still be quite good, however severe disease/death are lagging indicators and a definitive conclusion cannot be made at this time
Most therapeutic monoclonal antibodies currently approved by FDA and in use do not neutralize Omicron, however therapies targeting the host immune response are anticipated to retain effectiveness
Category
Epidemiology
Healthcare Services
Subject
Variants
Health Planning
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Reeder, B; Groot, G; Miller, L. What is the epidemiology of the Omicron variant and its impact on health care? 2021 Dec 22, Document no.: EOC211220 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 10 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC211220v022 ESR
Question Submitted
December 20, 2021
Date Completed
May 27, 2022
Status
3. Completed
Research Team
EOC
on Variants of Concern. [26 May 2022]. http://www.bccdc.ca/Health-Info- Site/Documents/VoC
Document Type
Evidence Search Report
Review Code
EOC211220v022 ESR
Question Submitted
December 20, 2021
Date Completed
May 27, 2022
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Healthcare Services
Subject
Health Planning
Variants
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 1 2-3 days
Cite As
Mueller, M; Miller, L. What is the epidemiology of the omicron variant and its impact on health care? 2022 May 27, Document no.: EOC211220v022 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 69 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC022201-01 ESR
Question Submitted
February 22, 2021
Date Completed
February 22, 2021
Status
3. Completed
Research Team
EOC
Evidence Search Report Review Question: What is the epidemiology of variants and what
Document Type
Evidence Search Report
Review Code
EOC022201-01 ESR
Question Submitted
February 22, 2021
Date Completed
February 22, 2021
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Healthcare Services
Subject
Variants
Health Planning
Population
All
Clinical Setting
Other
All
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L; Young, C. What is the epidemiology of variants and what are the implications for healthcare? 2021 Feb 22; Document no.: EOC022201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 28 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
December 17, 2021
Status
5. Updated review
Research Team
EOC
EVIDENCE SEARCH REPORT Review Question: What is the epidemiology of variants and what
Document Type
Evidence Search Report
Review Code
EOC031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
December 17, 2021
Status
5. Updated review
Research Team
EOC
Category
Epidemiology
Healthcare Services
Subject
Health Planning
Variants
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B.. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 17, Document no.: EOC031801v020 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 43 p. (CEST evidence search report).
Review History
EOC031801v18 RR
EOC031801v17 RR
EOC031801v16 RR
EOC031801v15 RR
EOC031801v14 RR
v012 and v013 RR were combined into v013
EOC031801v011 RR: August 27, 2021
v010 and v011 RR were combined into v011
EOC031801v9 RR: August 19, 2021
EOC031801v8 RR: July 12, 2021
EOC031801v7 RR; June 24, 2021
EOC031801v6 RR; June 17, 2021
EOC031801v5 RR; June 2, 2021
EOC031801v4 RR; May 17, 2021
EOC031801v3 RR: May 3, 2021
EOC031801v2 RR: April 20, 2021
EOC031801 RR: March 25, 2021
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 20, 2021
Status
5. Updated review
Research Team
EOC
: What is the epidemiology of variants and what are the implcations for healthcare? Review Code
Document Type
Table
Review Code
EOC031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 20, 2021
Status
5. Updated review
Research Team
EOC
Category
Epidemiology
Healthcare Services
Subject
Health Planning
Variants
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Asamoah, G; Badea, A; Hernandez-Ronquillo, L; Lee, S; Shumilak, G; Reeder, B; Groot, G; Muhajarine, N; Miller, L; Howell-Spooner, B. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 20. Document no.: EOC031801v019 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table).
Review History
EOC031801v18 RR
EOC031801v17 RR
EOC031801v16 RR
EOC031801v15 RR
EOC031801v14 RR
v012 and v013 RR were combined into v013
EOC031801v011 RR: August 27, 2021
v010 and v011 RR were combined into v011
EOC031801v9 RR: August 19, 2021
EOC031801v8 RR: July 12, 2021
EOC031801v7 RR; June 24, 2021
EOC031801v6 RR; June 17, 2021
EOC031801v5 RR; June 2, 2021
EOC031801v4 RR; May 17, 2021
EOC031801v3 RR: May 3, 2021
EOC031801v2 RR: April 20, 2021
EOC031801 RR: March 25, 2021
Related Documents
Documents

EOC031801v019 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 20, 2021
Status
5. Updated review
Research Team
EOC
Support Team RAPID REVIEW REPORT What is the epidemiology of variants and what are the implications
Document Type
Rapid Review
Review Code
EOC031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 20, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
December 20, 2021 - Delta dominance - Delta remains the predominant variant accounting for most of variants sequenced from surveillance data from Public Health Ontario, Public Health England and ECDC as of the 6th of December; this is rapidly changing. - Expect opinions from PHAC indicate that Omicron will likely outpace Delta and drive infections up to 26,600 a day by mid-January in Canada. - ECDC projects Omicron could cause over half of all SARS-CoV-2 infections in the EU/EEA within the next few months, with probability of further introduction and community spread and impact of the spread assessed HIGH and VERY HIGH respectively. - Preliminary evidence suggests that the various mutations in Omicron may increase transmissibility and replication; increase evasion of antibody neutralization by COVID-19 infection, vaccine-based, or monoclonal-based antibodies; increase the binding affinity of the virus to the ACE2 receptors on host cells; and may be associated with increased infectivity. - Evidence is still emerging on the disease severity with omicron compared to Delta, however the first Omicron death has been reported in the UK during the week of December 13, 2021. - The Delta sub-lineage AY.4.2 (Delta plus) continues account for an increasing proportion of Delta cases in the UK, with cases detected in Canada.
Key Findings
December 6, 2021 - A new SARS-CoV-2 variant designated Omicron has emerged and classified as a VOC by WHO. The heavily mutated variant (50 mutations -- 32 of them on the spike protein) was first identified in South Africa and has already spread to many parts of the world. - Preliminary evidence suggests there may be an increased risk of reinfection with Omicron, however, there is still emerging evidence of the transmissibility, severity of disease, effectiveness of vaccines, and the effectiveness of current tests and treatment. - Delta dominance - Delta remains the predominant variant accounting for most of variants sequenced from surveillance data from Public Health Ontario, Public Health England and ECDC. - The Delta sub-lineage AY.4.2 (Delta plus) continues account for an increasing proportion of Delta cases in the UK. - Delta variant sub-lineage AY.25 and AY.27 have been detected in Canada, with majority of the cases identified in Saskatchewan, followed by Alberta and B.C. However, experts say there’s no data to determine if these sub-lineages will be more transmissible than its parent strain.
Category
Epidemiology
Healthcare Services
Subject
Health Planning
Variants
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Asamoah, G; Badea, A; Lee, S; Shumilak, G; Reeder, B; Groot, G; Muhajarine, N; Hernandez-Ronquillo L; Miller, L; Howell-Spooner, B. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 20. Document no.: EOC031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 50 p. (CEST rapid review report).
Review History
EOC031801v18 RR
EOC031801v17 RR
EOC031801v16 RR
EOC031801v15 RR
EOC031801v14 RR
v012 and v013 RR were combined into v013
EOC031801v011 RR: August 27, 2021
v010 and v011 RR were combined into v011
EOC031801v9 RR: August 19, 2021
EOC031801v8 RR: July 12, 2021
EOC031801v7 RR; June 24, 2021
EOC031801v6 RR; June 17, 2021
EOC031801v5 RR; June 2, 2021
EOC031801v4 RR; May 17, 2021
EOC031801v3 RR: May 3, 2021
EOC031801v2 RR: April 20, 2021
EOC031801 RR: March 25, 2021
Related Documents
Documents
Less detail

11 records – page 1 of 2.